Matthew “Matt” Feshbach, founder and CEO of Ambrose Cell Therapy, Inc., takes a personalized approach to health science through his organization. Targeting chronic systemic inflammation, Matthew Feshbach and his team have developed a protocol that spans tissue harvesting and direct injections, as well as adipose-derived stem and regenerative cell (ADRC) preparation and delivery that helps reverse the impacts of stress-related inflammation in patients.
An underlying basis for ADRC are the links discovered between inflammation, stress, and issues with the immune system. There are numerous examples of these correlations in the medical literature, across chronic and acute conditions. One major example is of brain-related diseases involving cognitive decline.A study cited in an article on the Ambrose Cell Therapy website (https://ambrosecelltherapy.com/improving-cell-therapy-outcomes/) spanned 300 patients, living independently and with mild-to-severe Alzheimer’s disease. After being evaluated for baseline cognitive function by a caretaker, they were tested for Tumor Necrosis Factor alpha (TNF-a), a pro-inflammatory cytokine.
From this point forward in the study, participants recorded additional acute stressful systemic inflammatory events as they occurred. These ranged from physical trauma to illness.TNF-a and cognitive function were retested at two, four, and six months, and compared with initial baseline levels. The findings indicated that chronic and acute systemic inflammation (measured in TNF-a levels) was strongly correlated with cognitive decline.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.